Hepatic portal venous delivery of a nitric oxide synthase inhibitor enhances net hepatic glucose uptake

American Journal of Physiology - Endocrinology and Metabolism

Volumn 294, Issue 4, 2008, Pages

  Moore, Mary Courtney ^a   DiCostanzo, Catherine A ^a   Smith, Marta S ^a   Farmer, Ben ^a   Rodewald, Tiffany D ^a   Neal, Doss W ^a   Williams, Phillip E ^a   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

3 morpholynosydnonimine; Dog; NG nitro L arginine methyl ester

Indexed keywords

LINSIDOMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE DONOR; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ARTERY BLOOD FLOW; ARTICLE; CONTROLLED STUDY; DOG; DRUG MEGADOSE; ENZYME INHIBITION; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPERINSULINEMIA; INFUSION RATE; INSULIN RESISTANCE; LIVER; LIVER BLOOD FLOW; LIVER METABOLISM; LOW DRUG DOSE; MALE; NONHUMAN; PORTAL VEIN; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL;

ANIMALS; BLOOD GLUCOSE; CARBON; CATHETERIZATION; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FATTY ACIDS, NONESTERIFIED; FEMALE; GLYCEROL; HYPERGLYCEMIA; HYPERINSULINISM; LACTIC ACID; LIVER; MALE; MOLSIDOMINE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PORTAL VEIN; POSTPRANDIAL PERIOD;

EID: 41649092288     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00184.2007     Document Type: Article

References (43)

1. Alexander B, Rogers C, Naftalin R. Hepatic arterial perfusion decreases intrahepatic shunting and maintains glucose uptake in the rat liver. Pflugers Arch 444: 291-298, 2002.
2. An Z, DiCostanzo CA, Moore MC, Edgerton DS, Dardevet DP, Neal DW, Cherrington AD. Effects of the nitric oxide donor SIN-1 on net hepatic glucose uptake in the conscious dog. Am J Physiol Endocrinol Metab 294: E300-E306, 2008.
3. Basu A, Basu R, Shah P, Vella A, Johnson CM, Jensen M, Nair KS, Schwenk WF, Rizza RA. Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity. Diabetes 50: 1351-1362, 2001.
4. Bauer C, Walcher F, Kalweit U, Larsen R, Marzi I. Role of nitric oxide in the regulation of the hepatic microcirculation in vivo. J Hepatol 27: 1089-1095, 1997.
5. Ceriello A, Davidson J, Hanefeld M, Leiter L, Monnier L, Owens D, Tajima N, Tuomilehto J. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. Nutr Metab Cardiovasc Dis 16: 453-456, 2006.
6. Chen SS, Donmoyer CM, Ejiofor J, McCay J, Archuletta R, Lacy DB, McGuinness OP. Impact of intraportal N(omega)-nitro-L-arginine infusion on hepatic glucose metabolism in total parenteral nutrition-adapted dogs: interaction with infection. Metabolism 51: 274-283, 2002.
7. Cherrington AD. Banting Lecture 1997. Control of glucose uptake and release by the liver in vivo. Diabetes 48: 1198-1214, 1999.
8. Chu CA, Sindelar DK, Neal DW, Allen EJ, Donahue EP, Cherrington AD. Comparison of the direct and indirect effects of epinephrine on hepatic glucose production. J Clin Invest 99: 1044-1056, 1997.
9. Chu CA, Sindelar DK, Neal DW, Cherrington AD. Hepatic and gut clearance of catecholamines in the conscious dog. Metabolism 48: 259-263, 1999.
10. Conner EM, Aiko S, Fernandez M, Battarbee HD, Gray L, Grisham MB. Duration of the hemodynamic effects of N(G)-nitro-L-arginine methyl ester in vivo. Nitric Oxide 4: 85-93, 2000.
11. Cowan JS, Hetenyi G Jr. Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method. Metabolism 20: 360-372, 1971.
12. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 38: 337-343, 1995.
13. Galassetti P, Chu CA, Neal DW, Reed GW, Wasserman DH, Cherrington AD. A negative arterial-portal venous glucose gradient increases net hepatic glucose uptake in euglycemic dogs. Am J Physiol Endocrinol Metab 277: E126-E134, 1999.
14. Galassetti P, Shiota M, Zinker BA, Wasserman DH, Cherrington AD. A negative arterial-portal vein glucose gradient decreases skeletal muscle glucose uptake in the conscious dog. Am J Physiol Endocrinol Metab 275: E101-E111, 1998.
15. Gentilcore D, Visvanathan R, Russo A, Chaikomin R, Stevens JE, Wishart JM, Tonkin A, Horowitz M, Jones KL. Role of nitric oxide mechanisms in gastric emptying of, and the blood pressure and glycemic responses to, oral glucose in healthy older subjects. Am J Physiol Gastrointest Liver Physiol 288: G1227-G1232, 2005.
16. Guarino MP, Afonso RA, Raimundo N, Raposo JF, Macedo MP. Hepatic glutathione and nitric oxide are critical for hepatic insulin-sensitizing substance action. Am J Physiol Gastrointest Liver Physiol 284: G588-G594, 2003.
17. Guarino MP, Correia NC, Lautt WW, Macedo MP. Insulin sensitivity is mediated by the activation of the ACh/NO/cGMP pathway in rat liver. Am J Physiol Gastrointest Liver Physiol 287: G527-G532, 2004.
18. Holste LC, Connolly CC, Moore MC, Neal DW, Cherrington AD. Physiological changes in circulating glucagon alter hepatic glucose disposition during portal glucose delivery. Am J Physiol Endocrinol Metab 273: E488-E496, 1997.
19. Hsieh PS, Moore MC, Neal DW, Emshwiller M, Cherrington AD. Rapid reversal of the effects of the portal signal under hyperinsulinemic conditions in the conscious dog. Am J Physiol Endocrinol Metab 276: E930-E937, 1999.
20. Keppler D, Decker K. Glycogen: determination with amyloglucosidase. In: Methods in Enzymatic Analysis, edited by Bergmeyer HU. New York: Verlag Chemie Weinheim, Academic, 1974, p. 1127-1131.
21. Lautt WW. Practice and principles of pharmacodynamic determination of HISS-dependent and HISS-independent insulin action: methods to quantitate mechanisms of insulin resistance. Med Res Rev 23: 1-14, 2003.
22. Lautt WW, Macedo MP, Sadri P, Legare DJ, Reid MA, Guarino MP. Pharmaceutical reversal of insulin resistance. Proc West Pharmacol Soc 47: 30-32, 2004.
23. McGuinness OP, Donmoyer C, Ejiofor J, McElligott S, Lacy DB. Hepatic and muscle glucose metabolism during total parenteral nutrition: impact of infection. Am J Physiol Endocrinol Metab 275: E763-E769, 1998.
24. Moore MC, Burish MJ, Farmer B, Neal DW, Pan C, Cherrington AD. Chronic hepatic artery ligation does not prevent liver from differentiating portal vs. peripheral glucose delivery. Am J Physiol Endocrinol Metab 285: E845-E853, 2003.
25. Moore MC, Hsieh PS, Neal DW, Cherrington AD. Nonhepatic response to portal glucose delivery in conscious dogs. Am J Physiol Endocrinol Metab 279: E1271-E1277, 2000.
26. Moore MC, Satake S, Lautz M, Soleimanpour SA, Neal DW, Smith M, Cherrington AD. Nonesterified fatty acids and hepatic glucose metabolism in the conscious dog. Diabetes 53: 32-40, 2004.
27. Myers SR, McGuinness OP, Neal DW, Cherrington AD. Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration. J Clin Invest 87: 930-939, 1991.
28. Pagliassotti MJ, Holste LC, Moore MC, Neal DW, Cherrington AD. Comparison of the time courses of insulin and the portal signal on hepatic glucose and glycogen metabolism in the dog. J Clin Invest 97: 81-91, 1996.
29. Pencek RR, Shearer J, Camacho RC, James FD, Lacy DB, Fueger PT, Donahue EP, Snead W, Wasserman DH. 5-Aminoimidazole-4-carboxamide-1-beta- D-ribofuranoside causes acute hepatic insulin resistance in vivo. Diabetes 54: 355-360, 2005.
30. Picker O, Scheeren TW, Arndt JO. Nitric oxide synthases in vagal neurons are crucial for the regulation of heart rate in awake dogs. Basic Res Cardiol 96: 395-404, 2001.
31. Rossoni G, Manfredi B, De Gennaro Colonna V, Berti M, Guazzi M, Berti F. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol 150: 567-576, 2007.
32. Sadri P, Lautt WW. Blockade of hepatic nitric oxide synthase causes insulin resistance. Am J Physiol Gastrointest Liver Physiol 277: G101-G108, 1999.
33. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85: 4053-4059, 2000.
34. Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49: 684-687, 2000.
35. Shiota M, Jackson P, Galassetti P, Scott M, Neal DW, Cherrington AD. Combined intraportal infusion of acetylcholine and adrenergic blockers augments net hepatic glucose uptake. Am J Physiol Endocrinol Metab 278: E544-E552, 2000.
36. Sprangers F, Sauerwein HP, Romijn JA, van Woerkom GM, Meijer AJ. Nitric oxide inhibits glycogen synthesis in isolated rat hepatocytes. Biochem J 330: 1045-1049, 1998.
37. Steele R, Wall JS, DeBodo RC, Altszuler N. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. Am J Physiol 187: 15-24, 1956.
38. Tarsitano CA, Paffaro VA Jr, Pauli JR, da Silva GH, Saad MJ, Salgado I, da Cruz-Höfling MA, Hyslop S. Hepatic morphological alterations, glycogen content and cytochrome P450 activities in rats treated chronically with N(omega)-nitro-L-arginine methyl ester (L-NAME). Cell Tissue Res 329: 45-58, 2007.
39. Thrasher TN, Shifflett C. Effect of carotid or aortic baroreceptor denervation on arterial pressure during hemorrhage in conscious dogs. Am J Physiol Regul Integr Comp Physiol 280: R1642-R1649, 2001.
40. Tsuchiya K, Sakai H, Suzuki N, Iwashima F, Yoshimoto T, Shichiri M, Hirata Y. Chronic blockade of nitric oxide synthesis reduces adiposity and improves insulin resistance in high fat-induced obese mice. Endocrinology 148: 4548-4556, 2007.
41. van der Linde NA, Boomsma F, van den Meiracker AH. Potentiation of L-NAME-induced systemic and renal vasoconstrictor responses by alpha1-adrenoceptor antagonism. J Hypertens 23: 1017-1024, 2005.
42. Walkowska A, Badzynska B, Kompanowska-Jezierska E, Johns EJ, Sadowski J. Effects of renal nerve stimulation on intrarenal blood flow in rats with intact or inactivated NO synthases. Acta Physiol Scand 183: 99-105, 2005.
43. Zou MH, Hou XY, Shi CM, Kirkpatick S, Liu F, Goldman MH, Cohen RA. Activation of 5′-AMP-activated kinase is mediated through c-Src and phosphoinositide 3-kinase activity during hypoxia-reoxygenation of bovine aortic endothelial cells. Role of peroxynitrite. J Biol Chem 278: 34003-34010, 2003.